Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2–Related Mechanism
Saved in:
| Published in: | Clinical colorectal cancer Vol. 15; no. 4; pp. e229 - e234 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01.12.2016
|
| Subjects: | |
| ISSN: | 1533-0028, 1938-0674, 1938-0674 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Author | Kim, Stefano Arbez-Gindre, Francine Nguyen, Thierry Jacquin, Marion Borg, Christophe Lakkis, Zaher Jary, Marine Cayre, Anne Fein, Francine |
|---|---|
| Author_xml | – sequence: 1 givenname: Stefano orcidid: 0000-0003-2851-7119 surname: Kim fullname: Kim, Stefano email: chkim@chu-besancon.fr organization: Department of Medical Oncology, University Hospital of Besançon, Besançon, France – sequence: 2 givenname: Anne surname: Cayre fullname: Cayre, Anne organization: Department of Pathology, Jean Perrin Center, Clermont-Ferrand, France – sequence: 3 givenname: Marine surname: Jary fullname: Jary, Marine organization: Department of Medical Oncology, University Hospital of Besançon, Besançon, France – sequence: 4 givenname: Marion surname: Jacquin fullname: Jacquin, Marion organization: Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France – sequence: 5 givenname: Francine surname: Arbez-Gindre fullname: Arbez-Gindre, Francine organization: Department of Pathology, University Hospital of Besançon, Besançon, France – sequence: 6 givenname: Francine surname: Fein fullname: Fein, Francine organization: Department of Gastroenterology, University Hospital of Besançon, Besançon, France – sequence: 7 givenname: Zaher orcidid: 0000-0002-2608-5896 surname: Lakkis fullname: Lakkis, Zaher organization: Department of Digestive Surgery and Liver Transplantation, University Hospital of Besançon, Besançon, France – sequence: 8 givenname: Thierry surname: Nguyen fullname: Nguyen, Thierry organization: Department of Medical Oncology, University Hospital of Besançon, Besançon, France – sequence: 9 givenname: Christophe surname: Borg fullname: Borg, Christophe organization: Department of Medical Oncology, University Hospital of Besançon, Besançon, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27600470$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstuEzEUhkeoiF7gBVggL9lMsD2TuVQIKURNiRSUKlx3lufMGdXBsVPbUxRWvAMPxXvwJHiawqISZeUj6_-_Y5__HCcHxhpMkqeMjhhlxYv1CDTAiMd6RMsRZeMHyRGrsyqlRZkfxHqcZSmlvDpMjr1fx6rIGHuUHPKyoDQv6VHyc2o3W40ByQr91hqPJFgy6bRq0AFuQzpbLmbz1ZwoQ5YGyYUMCk0gn1S4JFOrrUMIUpOpNIAuUjonIVi3Gziv8VqC-tZvZHPDWX4-JRNyYb1XjUYy6YMFpyL1o_TQa-nImWltuEStIvLc2a-xyeyGF8nDc2LBf33_sUItA7bkLcKlNMpvHicPO6k9Prk9T5IPs7P30zfpYnk-n04WKeQFD2mdFx3UQLsSIccOWAvQZLJrGJRlw7tmuG1iJ5pnkFW8olmNsuAM2wKrPM9Okud77tbZqx59EBvlAbWWBm3vBavGdZmxqh5H6bNbad9ssBVbpzbS7cSf4UcB3wvAxYk47P5KGBVDwmIthoTFkLCgpYgJR1N1xwQqxEysCU4qfb_15d6KcUDXCp3wELMEbNUQomitut_-6o4dtDIKpP6CO_Rr2zsTRy-Y8FxQ8W7YvmH5WJFRxvnw39N_A_7X_TfM8O3M |
| CitedBy_id | crossref_primary_10_1097_RLU_0000000000002611 crossref_primary_10_1007_s40278_017_25618_1 crossref_primary_10_36290_xon_2019_045 |
| Cites_doi | 10.1016/S1470-2045(15)70127-0 10.1002/gcc.21922 10.1038/srep17946 10.1056/NEJMoa032691 10.1002/cncr.21783 10.2119/molmed.2009.00119 10.1016/S0140-6736(12)61900-X 10.1093/glycob/cwl025 10.1038/bjc.2011.85 10.1200/JCO.2009.24.8252 10.1038/nature10144 10.1200/JCO.2005.03.4645 10.1007/s10456-011-9249-6 10.1158/1535-7163.MCT-13-0753 10.1016/j.cell.2014.01.059 10.1186/s12885-015-1130-3 10.1200/jco.2015.33.3_suppl.638 10.1200/JCO.2012.42.8201 10.1200/JCO.2007.14.9930 10.1038/nrc1527 10.1016/j.ctrv.2011.12.008 10.1002/ijc.25441 10.1158/0008-5472.CAN-10-2614 10.1172/JCI65385 10.1111/j.1440-1789.2011.01204.x 10.1016/S1470-2045(12)70477-1 10.1200/JCO.2006.09.6305 10.1038/nrclinonc.2009.110 10.1016/S1470-2045(15)70156-7 10.1677/erc.1.01221 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Inc. Elsevier Inc. |
| Copyright_xml | – notice: 2016 Elsevier Inc. – notice: Elsevier Inc. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.clcc.2016.07.015 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1938-0674 |
| EndPage | e234 |
| ExternalDocumentID | 27600470 10_1016_j_clcc_2016_07_015 S1533002816301220 1_s2_0_S1533002816301220 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 5VS 6J9 6PF 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEGXH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EFKBS EFLBG EJD EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OC~ OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ T5K TEORI UDS Z5R ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW EMB SV3 AAIAV ABLVK ABYKQ AJBFU LCYCR AAYXX CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c462t-946fc9c0f7ec4efc1dccb3afb1c77b2fbc4efbece043c3828039ea621ed6e8443 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000392712600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1533-0028 1938-0674 |
| IngestDate | Wed Oct 01 10:31:02 EDT 2025 Wed Feb 19 02:42:46 EST 2025 Wed Oct 29 21:24:40 EDT 2025 Tue Nov 18 21:09:39 EST 2025 Fri Feb 23 02:33:50 EST 2024 Tue Feb 25 20:07:56 EST 2025 Tue Oct 14 19:24:45 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | VEGFR2 KDR Biomarker Case report Predictive |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c462t-946fc9c0f7ec4efc1dccb3afb1c77b2fbc4efbece043c3828039ea621ed6e8443 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0003-2851-7119 0000-0002-2608-5896 |
| PMID | 27600470 |
| PQID | 1859731895 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1859731895 pubmed_primary_27600470 crossref_primary_10_1016_j_clcc_2016_07_015 crossref_citationtrail_10_1016_j_clcc_2016_07_015 elsevier_sciencedirect_doi_10_1016_j_clcc_2016_07_015 elsevier_clinicalkeyesjournals_1_s2_0_S1533002816301220 elsevier_clinicalkey_doi_10_1016_j_clcc_2016_07_015 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-12-01 |
| PublicationDateYYYYMMDD | 2016-12-01 |
| PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical colorectal cancer |
| PublicationTitleAlternate | Clin Colorectal Cancer |
| PublicationYear | 2016 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Grothey, Cutsem, Sobrero (bib7) 2013; 381 Yang, Tang, Riquelme (bib16) 2011; 71 Hurwitz, Fehrenbacher, Novotny (bib1) 2004; 350 Grothey, Galanis (bib10) 2009; 6 Gaya, Tse (bib11) 2012; 38 Saltz, Clarke, Díaz-Rubio (bib2) 2008; 26 Kopetz, Hoff, Morris (bib30) 2010; 28 Carmeliet, Jain (bib14) 2011; 473 Liu, Rabinovich (bib25) 2005; 5 Bennouna, Sastre, Arnold (bib4) 2013; 14 Chatterjee, Heukamp, Siobal (bib15) 2013; 123 Chung, Yoon, Zerkowski (bib19) 2006; 106 Papadopoulos, Martin, Ruan (bib12) 2012; 15 Spano, Russo, Di Maso (bib24) 2010; 16 Van Cutsem, Tabernero, Lakomý (bib5) 2012; 30 Camby, Le Mercier, Lefranc, Kiss (bib26) 2006; 16 Tabernero, Yoshino, Cohn (bib6) 2015; 16 Stanley (bib27) 2014; 156 Giantonio, Catalano, Meropol (bib3) 2007; 25 Wedam, Low, Yang (bib9) 2006; 24 Loupakis, Cremolini, Fioravanti (bib31) 2011; 104 Hoff, Van Hazel, Cunningham (bib29) 2016; 32 Nobusawa, Stawski, Kim, Nakazato, Ohgaki (bib20) 2011; 31 Jayasinghe, Simiantonaki, Kirkpatrick (bib22) 2014; 15 Johansson, Aaltonen, Ebbesson (bib18) 2012; 51 Sims, Gao, Phillips, Lowy (bib28) 2015; 33 Li, Qin, Xu (bib8) 2015; 16 Liang (bib17) 2006; 13 Kanda, Noda, Saito, Ishida (bib23) 2015; 5 Chiron, Bagley, Pollard (bib13) 2014; 13 Silva, Bowen, Rychahou (bib21) 2011; 128 Grothey (10.1016/j.clcc.2016.07.015_bib10) 2009; 6 Spano (10.1016/j.clcc.2016.07.015_bib24) 2010; 16 Kopetz (10.1016/j.clcc.2016.07.015_bib30) 2010; 28 Jayasinghe (10.1016/j.clcc.2016.07.015_bib22) 2014; 15 Sims (10.1016/j.clcc.2016.07.015_bib28) 2015; 33 Giantonio (10.1016/j.clcc.2016.07.015_bib3) 2007; 25 Hurwitz (10.1016/j.clcc.2016.07.015_bib1) 2004; 350 Johansson (10.1016/j.clcc.2016.07.015_bib18) 2012; 51 Tabernero (10.1016/j.clcc.2016.07.015_bib6) 2015; 16 Chiron (10.1016/j.clcc.2016.07.015_bib13) 2014; 13 Bennouna (10.1016/j.clcc.2016.07.015_bib4) 2013; 14 Silva (10.1016/j.clcc.2016.07.015_bib21) 2011; 128 Liang (10.1016/j.clcc.2016.07.015_bib17) 2006; 13 Grothey (10.1016/j.clcc.2016.07.015_bib7) 2013; 381 Gaya (10.1016/j.clcc.2016.07.015_bib11) 2012; 38 Camby (10.1016/j.clcc.2016.07.015_bib26) 2006; 16 Hoff (10.1016/j.clcc.2016.07.015_bib29) 2016; 32 Loupakis (10.1016/j.clcc.2016.07.015_bib31) 2011; 104 Chung (10.1016/j.clcc.2016.07.015_bib19) 2006; 106 Papadopoulos (10.1016/j.clcc.2016.07.015_bib12) 2012; 15 Saltz (10.1016/j.clcc.2016.07.015_bib2) 2008; 26 Kanda (10.1016/j.clcc.2016.07.015_bib23) 2015; 5 Yang (10.1016/j.clcc.2016.07.015_bib16) 2011; 71 Van Cutsem (10.1016/j.clcc.2016.07.015_bib5) 2012; 30 Wedam (10.1016/j.clcc.2016.07.015_bib9) 2006; 24 Liu (10.1016/j.clcc.2016.07.015_bib25) 2005; 5 Li (10.1016/j.clcc.2016.07.015_bib8) 2015; 16 Chatterjee (10.1016/j.clcc.2016.07.015_bib15) 2013; 123 Carmeliet (10.1016/j.clcc.2016.07.015_bib14) 2011; 473 Nobusawa (10.1016/j.clcc.2016.07.015_bib20) 2011; 31 Stanley (10.1016/j.clcc.2016.07.015_bib27) 2014; 156 |
| References_xml | – volume: 473 start-page: 298 year: 2011 end-page: 307 ident: bib14 article-title: Molecular mechanisms and clinical applications of angiogenesis publication-title: Nature – volume: 38 start-page: 484 year: 2012 end-page: 493 ident: bib11 article-title: A preclinical and clinical review of aflibercept for the management of cancer publication-title: Cancer Treat Rev – volume: 14 start-page: 29 year: 2013 end-page: 37 ident: bib4 article-title: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial publication-title: Lancet Oncol – volume: 51 start-page: 375 year: 2012 end-page: 383 ident: bib18 article-title: Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis publication-title: Genes Chromosomes Cancer – volume: 13 start-page: 1636 year: 2014 end-page: 1644 ident: bib13 article-title: Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer publication-title: Mol Cancer Ther – volume: 31 start-page: 583 year: 2011 end-page: 588 ident: bib20 article-title: Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study publication-title: Neuropathology – volume: 24 start-page: 769 year: 2006 end-page: 777 ident: bib9 article-title: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer publication-title: J Clin Oncol – volume: 5 start-page: 29 year: 2005 end-page: 41 ident: bib25 article-title: Galectins as modulators of tumour progression publication-title: Nat Rev Cancer – volume: 28 start-page: 453 year: 2010 end-page: 459 ident: bib30 article-title: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance publication-title: J Clin Oncol – volume: 381 start-page: 303 year: 2013 end-page: 312 ident: bib7 article-title: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial publication-title: Lancet – volume: 106 start-page: 1677 year: 2006 end-page: 1684 ident: bib19 article-title: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray publication-title: Cancer – volume: 25 start-page: 1539 year: 2007 end-page: 1544 ident: bib3 article-title: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 publication-title: J Clin Oncol – volume: 128 start-page: 1045 year: 2011 end-page: 1056 ident: bib21 article-title: VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis publication-title: Int J Cancer – volume: 16 start-page: 102 year: 2010 end-page: 115 ident: bib24 article-title: Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness publication-title: Mol Med – volume: 26 start-page: 2013 year: 2008 end-page: 2019 ident: bib2 article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study publication-title: J Clin Oncol – volume: 123 start-page: 1732 year: 2013 end-page: 1740 ident: bib15 article-title: Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer publication-title: J Clin Invest – volume: 15 start-page: 104 year: 2014 ident: bib22 article-title: Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis publication-title: BMC Cancer – volume: 33 start-page: abstr 638 year: 2015 ident: bib28 article-title: Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial publication-title: J Clin Oncol – volume: 104 start-page: 1262 year: 2011 end-page: 1269 ident: bib31 article-title: Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer publication-title: Br J Cancer – volume: 30 start-page: 3499 year: 2012 end-page: 3506 ident: bib5 article-title: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen publication-title: J Clin Oncol – volume: 16 start-page: 619 year: 2015 end-page: 629 ident: bib8 article-title: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol – volume: 16 start-page: 499 year: 2015 end-page: 508 ident: bib6 article-title: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study publication-title: Lancet Oncol – volume: 6 start-page: 507 year: 2009 end-page: 518 ident: bib10 article-title: Targeting angiogenesis: progress with anti-VEGF treatment with large molecules publication-title: Nat Rev Clin Oncol – volume: 16 start-page: 137R year: 2006 end-page: 157R ident: bib26 article-title: Galectin-1: a small protein with major functions publication-title: Glycobiology – volume: 156 start-page: 625 year: 2014 end-page: 626 ident: bib27 article-title: Galectin-1 pulls the strings on VEGFR2 publication-title: Cell – volume: 71 start-page: 5512 year: 2011 end-page: 5521 ident: bib16 article-title: Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy publication-title: Cancer Res – volume: 13 start-page: 905 year: 2006 end-page: 919 ident: bib17 article-title: Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones publication-title: Endocr Relat Cancer – volume: 350 start-page: 2335 year: 2004 end-page: 2342 ident: bib1 article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med – volume: 15 start-page: 171 year: 2012 end-page: 185 ident: bib12 article-title: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab publication-title: Angiogenesis – volume: 32 start-page: 3639 year: 2016 ident: bib29 article-title: The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression 9 months (mos) versus < 9 mos publication-title: J Clin Oncol – volume: 5 start-page: 17946 year: 2015 ident: bib23 article-title: Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy publication-title: Sci Rep – volume: 16 start-page: 499 year: 2015 ident: 10.1016/j.clcc.2016.07.015_bib6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70127-0 – volume: 51 start-page: 375 year: 2012 ident: 10.1016/j.clcc.2016.07.015_bib18 article-title: Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.21922 – volume: 5 start-page: 17946 year: 2015 ident: 10.1016/j.clcc.2016.07.015_bib23 article-title: Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy publication-title: Sci Rep doi: 10.1038/srep17946 – volume: 350 start-page: 2335 year: 2004 ident: 10.1016/j.clcc.2016.07.015_bib1 article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa032691 – volume: 106 start-page: 1677 year: 2006 ident: 10.1016/j.clcc.2016.07.015_bib19 article-title: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray publication-title: Cancer doi: 10.1002/cncr.21783 – volume: 16 start-page: 102 year: 2010 ident: 10.1016/j.clcc.2016.07.015_bib24 article-title: Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness publication-title: Mol Med doi: 10.2119/molmed.2009.00119 – volume: 381 start-page: 303 year: 2013 ident: 10.1016/j.clcc.2016.07.015_bib7 article-title: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(12)61900-X – volume: 16 start-page: 137R year: 2006 ident: 10.1016/j.clcc.2016.07.015_bib26 article-title: Galectin-1: a small protein with major functions publication-title: Glycobiology doi: 10.1093/glycob/cwl025 – volume: 104 start-page: 1262 year: 2011 ident: 10.1016/j.clcc.2016.07.015_bib31 article-title: Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer publication-title: Br J Cancer doi: 10.1038/bjc.2011.85 – volume: 28 start-page: 453 year: 2010 ident: 10.1016/j.clcc.2016.07.015_bib30 article-title: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.8252 – volume: 473 start-page: 298 year: 2011 ident: 10.1016/j.clcc.2016.07.015_bib14 article-title: Molecular mechanisms and clinical applications of angiogenesis publication-title: Nature doi: 10.1038/nature10144 – volume: 24 start-page: 769 year: 2006 ident: 10.1016/j.clcc.2016.07.015_bib9 article-title: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.4645 – volume: 15 start-page: 171 year: 2012 ident: 10.1016/j.clcc.2016.07.015_bib12 article-title: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab publication-title: Angiogenesis doi: 10.1007/s10456-011-9249-6 – volume: 13 start-page: 1636 year: 2014 ident: 10.1016/j.clcc.2016.07.015_bib13 article-title: Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-13-0753 – volume: 156 start-page: 625 year: 2014 ident: 10.1016/j.clcc.2016.07.015_bib27 article-title: Galectin-1 pulls the strings on VEGFR2 publication-title: Cell doi: 10.1016/j.cell.2014.01.059 – volume: 15 start-page: 104 year: 2014 ident: 10.1016/j.clcc.2016.07.015_bib22 article-title: Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis publication-title: BMC Cancer doi: 10.1186/s12885-015-1130-3 – volume: 33 start-page: abstr 638 issue: suppl 3 year: 2015 ident: 10.1016/j.clcc.2016.07.015_bib28 article-title: Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.3_suppl.638 – volume: 30 start-page: 3499 year: 2012 ident: 10.1016/j.clcc.2016.07.015_bib5 article-title: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.8201 – volume: 26 start-page: 2013 year: 2008 ident: 10.1016/j.clcc.2016.07.015_bib2 article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.9930 – volume: 5 start-page: 29 year: 2005 ident: 10.1016/j.clcc.2016.07.015_bib25 article-title: Galectins as modulators of tumour progression publication-title: Nat Rev Cancer doi: 10.1038/nrc1527 – volume: 38 start-page: 484 year: 2012 ident: 10.1016/j.clcc.2016.07.015_bib11 article-title: A preclinical and clinical review of aflibercept for the management of cancer publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2011.12.008 – volume: 128 start-page: 1045 year: 2011 ident: 10.1016/j.clcc.2016.07.015_bib21 article-title: VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis publication-title: Int J Cancer doi: 10.1002/ijc.25441 – volume: 71 start-page: 5512 year: 2011 ident: 10.1016/j.clcc.2016.07.015_bib16 article-title: Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2614 – volume: 123 start-page: 1732 year: 2013 ident: 10.1016/j.clcc.2016.07.015_bib15 article-title: Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer publication-title: J Clin Invest doi: 10.1172/JCI65385 – volume: 31 start-page: 583 year: 2011 ident: 10.1016/j.clcc.2016.07.015_bib20 article-title: Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study publication-title: Neuropathology doi: 10.1111/j.1440-1789.2011.01204.x – volume: 14 start-page: 29 year: 2013 ident: 10.1016/j.clcc.2016.07.015_bib4 article-title: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70477-1 – volume: 25 start-page: 1539 year: 2007 ident: 10.1016/j.clcc.2016.07.015_bib3 article-title: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.6305 – volume: 6 start-page: 507 year: 2009 ident: 10.1016/j.clcc.2016.07.015_bib10 article-title: Targeting angiogenesis: progress with anti-VEGF treatment with large molecules publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2009.110 – volume: 16 start-page: 619 year: 2015 ident: 10.1016/j.clcc.2016.07.015_bib8 article-title: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70156-7 – volume: 13 start-page: 905 year: 2006 ident: 10.1016/j.clcc.2016.07.015_bib17 article-title: Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones publication-title: Endocr Relat Cancer doi: 10.1677/erc.1.01221 – volume: 32 start-page: 3639 issue: 15 suppl year: 2016 ident: 10.1016/j.clcc.2016.07.015_bib29 article-title: The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression 9 months (mos) versus < 9 mos publication-title: J Clin Oncol |
| SSID | ssj0026311 |
| Score | 2.090551 |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e229 |
| SubjectTerms | Biomarker Case report Gastroenterology and Hepatology Hematology, Oncology and Palliative Medicine KDR Predictive VEGFR2 |
| Title | Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2–Related Mechanism |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1533002816301220 https://www.clinicalkey.es/playcontent/1-s2.0-S1533002816301220 https://dx.doi.org/10.1016/j.clcc.2016.07.015 https://www.ncbi.nlm.nih.gov/pubmed/27600470 https://www.proquest.com/docview/1859731895 |
| Volume | 15 |
| WOSCitedRecordID | wos000392712600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1938-0674 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0026311 issn: 1533-0028 databaseCode: AIEXJ dateStart: 20010501 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeENdRLpOReKuCmsS58RZQC53YWsFAfbMS15E6tUnpTRP_jz_CL-Gc2E7Ctg54QKqiyImPU53Px8fH50LIK9j3ZLIrpeUEibBYkCVWIoLASmGtRI3BZ6Eoi00Ep6fheByNWq2fJhZmOwvyPLy4iBb_ldXQBszG0Nl_YHdFFBrgHpgOV2A7XP-K8TjDgRlYj6F0fy1rY8RZ6UeCPixWf_ixP_g0QEvHEFTMkcqsCvIBw5FAFqIMRJMC4mEJVLJlWZOnVFPfym0ipt838yQt6QzHKrR9VODcmslOvFkXAiMKO1-Nj2svn2CY1wxt8-9h1w_D9EuKqLPCB8GNY5VOeaD8nkgMRTZ5DU0KBRO-KerPE-Xn1S4Ec-2zliV5UR-saBN7nNfeA8eJ8hw4SZbTZqv4tlH5FPCBBqs2h9h-w7VEKhEegQiHNZj9JuO9BpZZQ2BLRxlcrqwkyqhx_lrMBGa6tFWOV0WngaLFvISRg-ebTJVAuZS_2zzaIwdO4EUgeQ_iQW98XJkFfNe2dTiX8jy8PCQmrNZEdmlPu3ZHpZZ0do_c1dsbGitY3ictmT8gt0-0A8dD8sOgkxp00nVBr0EnneYU0Ek1Oimik9bopAqdtEYn0rmKzjc0pgabtMImNdikDWxShU2qsEkNNmmFTVph8xH50u-dvftg6UoilmC-s7Yi5mciEt0skILJTNgTIVI3yVIb5FLqZCm2gjSTXeYKN8SKbZFMfMeWE1-GjLmPyX5e5PIJoaG2cmRO4rA0ncDP9lCwpUJMPF-0iW04xIVOs4_VXmbc-FOec2QwRwbzbsCBwW3SqfosVJKZG992DeO5CZ-GBZ8Dcm_sFVzXS6606Fpxm68c3uWfcQeIphjYqeG5e7dNvKqnVsuVuv3HEV8aVHJYs_AgMsllsYGRQg8r5oURvHOo4Fr9b4P0pzufPCN36on_nOyvlxv5gtwS2_V0tTwie8E4PNJz7BcHqRew |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Complete+Response+to+Aflibercept-FOLFIRI+in+One+Patient+With+Colorectal+Cancer+Refractory+to+Bevacizumab-FOLFOX%3A+A+Possible+Autocrine+Vascular+Endothelial+Growth+Factor+Receptor+2-Related+Mechanism&rft.jtitle=Clinical+colorectal+cancer&rft.au=Kim%2C+Stefano&rft.au=Cayre%2C+Anne&rft.au=Jary%2C+Marine&rft.au=Jacquin%2C+Marion&rft.date=2016-12-01&rft.eissn=1938-0674&rft.volume=15&rft.issue=4&rft.spage=e229&rft_id=info:doi/10.1016%2Fj.clcc.2016.07.015&rft_id=info%3Apmid%2F27600470&rft.externalDocID=27600470 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15330028%2FS1533002816X00059%2Fcov150h.gif |